Prime Medicine, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Prime Medicine, Inc. (PRME) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$659.00K.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.22M, a 254.75% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$2.60M, a 140.61% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.30M, a 118.67% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$4.54M, a 128.66% decline from fiscal 2024.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $15.86M, a 67.73% increase from fiscal 2023.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $9.46M, a 444.02% increase from fiscal 2022.
- Prime Medicine, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.74M, a 96.38% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$659.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.88M 10-Q · filed 2026-08-06 | -$4.48M derived: sum of 3 quarters · filed 2026-08-06 | -$5.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.22M 10-Q · filed 2026-05-07 | -$3.82M derived: sum of 2 quarters · filed 2026-05-07 | -$5.11M derived: sum of 3 quarters · filed 2026-05-07 | -$6.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.89M derived: sum of 2 quarters · filed 2026-03-03 | -$5.33M derived: sum of 3 quarters · filed 2026-08-06 | -$4.54M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$2.74M derived: sum of 2 quarters · filed 2026-08-06 | -$1.95M 10-Q · filed 2025-11-07 | $4.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$652.00K 10-Q · filed 2026-08-06 | $5.74M derived: sum of 3 quarters · filed 2026-08-06 | $12.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $789.00K 10-Q · filed 2026-05-07 | $7.18M derived: sum of 2 quarters · filed 2026-05-07 | $14.13M derived: sum of 3 quarters · filed 2026-05-07 | $13.85M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $13.34M derived: sum of 2 quarters · filed 2026-03-03 | $13.06M derived: sum of 3 quarters · filed 2026-03-03 | $15.86M 10-K · filed 2026-03-03 |
| 2024-09-30 | $6.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $6.67M derived: sum of 2 quarters · filed 2025-11-07 | $9.47M 10-Q · filed 2025-11-07 | $9.88M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.52M 10-Q · filed 2025-08-07 | $2.93M derived: sum of 3 quarters · filed 2025-08-07 | $6.67M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.79M 10-Q · filed 2025-05-08 | $3.21M derived: sum of 2 quarters · filed 2025-05-08 | $6.95M derived: sum of 3 quarters · filed 2025-05-08 | $10.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $4.16M derived: sum of 2 quarters · filed 2025-02-28 | $8.17M derived: sum of 3 quarters · filed 2025-02-28 | $9.46M 10-K · filed 2025-02-28 |
| 2023-09-30 | $3.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.75M derived: sum of 2 quarters · filed 2024-11-12 | $9.04M 10-Q · filed 2024-11-12 | $9.70M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.30M 10-Q · filed 2024-08-08 | $5.96M derived: sum of 3 quarters · filed 2024-08-08 | $6.99M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.28M 10-Q · filed 2024-05-10 | $1.94M derived: sum of 2 quarters · filed 2024-05-10 | $2.98M derived: sum of 3 quarters · filed 2024-05-10 | $3.31M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.70M derived: sum of 2 quarters · filed 2024-03-01 | $2.03M derived: sum of 3 quarters · filed 2024-03-01 | $1.74M 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.37M derived: sum of 2 quarters · filed 2023-11-03 | $1.08M 10-Q · filed 2023-11-03 | $1.32M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $43.00K 10-Q · filed 2023-08-07 | $286.00K derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$292.00K 10-Q · filed 2023-05-11 | -$49.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $885.00K 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $642.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $388.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |